参考资料 [1]Chen J,et al.Measurable residual disease (MRD)-testing in haematological and solid cancers[J]. Leukemia, 2024, 38(6): 1202-1212.https://www.nature.com/articles/s41375-024-02252-4 [2]Shaw JA,et al.Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value...
参考文献 [1]. NCCN Guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma. Foresight Diagnostics. January 10, 2025. Accessed January 10, 2025. [2]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelin...
是否必须要做? 当癌症难以通过常规手段(如血液检查、活检,以及 18F - 脱氧葡萄糖正电子发射断层扫描(PET)、计算机断层扫描(CT)、磁共振成像(MRI)等影像学检查)被检测到时,微小残留病灶(MRD)检测便受到了广泛关注。MRD 检测能够辅助医生更精准地判断病情,对...
当癌症难以通过常规手段(如血液检查、活检,以及 18F - 脱氧葡萄糖正电子发射断层扫描(PET)、计算机断层扫描(CT)、磁共振成像(MRI)等影像学检查)被检测到时,微小残留病灶(MRD)检测便受到了广泛关注。MRD 检测能够辅助医生更精准地判断病情,对提升患者的治疗效果、改善预后及生活质量均具有重要意义。 何谓微小残留病灶...
图5. MRD testing in early stage breast cancer. A and B, Kaplan–Meier curves showing distant recurrence-free survival for patients treated for early-stage breast cancer and in whom MRD was detected or not at the postoperative and year1 (Y1) time points. Postoperative and Y1 blood samples we...
2. Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers. Speaker: Everett Moding, MD PhD. Date: Tuesday September 28, 2021 at 2:00pm Eastern. Meeting: Utility of Cell-free DNA in the Clinic: Current State and Future Directions ...
Clinical Testing Services 临床检测服务 YuceOne®Monitor 套餐YuceOne®MRD YuceOne®MRD YuceOne®MRD 本检测根据全外显子(WES)检测为患者定制个体化ctDNA监测panel, 采⽤⽬标基因捕获⼆代测序(NGS)技术,全⾯精准地检测与肿瘤发⽣发展或临床治疗相关的基因变异,为肿瘤患者的术后复发风险,及药物疗效...
2. Webinar #3: Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers. Speaker: Everett Moding, MD PhD. Date: Tuesday September 28, 2021 at 2:00pm Eastern. Meeting: Utility of Cell-free DNA in the Clinic: Current State and Future Directions ...
2020年8月,Genosity公司的MRD检测三部曲Astra™ testing system成为CLIA认证的LDT检测。该检测体系包含以下3个部分: Astra Profile™, 在Illumina NovaSeq™ 6000 平台上的全外显子测序,形成个体化肿瘤分子谱;Astra One™, 第二步,基于无创液体活检的初步MRD评估;Astra Next™, 在病程中对MRD的持续监测。
Ultrasensitive ctDNA testing delivers the insights you need to make confident treatment decisions. Transformative technology Haystack MRD is the culmination of 20 years of liquid biopsy research and innovation by the pioneers of cancer genomics who understood the need to detect low-abundance DNA molecu...